Global impact of rotavirus vaccines

Expert Review of Vaccines

Volumn 9, Issue 4, 2010, Pages 395-407

  Tate, Jacqueline E ^a   Patel, Manish M ^a   Steele, A Duncan ^b   Gentsch, Jon R ^a   Payne, Daniel C ^a   Cortese, Margaret M ^a   Nakagomi, Osamu ^c   Cunliffe, Nigel A ^d   Jiang, Baoming ^a   Neuzil, Kathleen M ^b   De Oliveira, Lucia H ^e   Glass, Roger I ^f   Parashar, Umesh D ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b PATH   (United States)

^c NAGASAKI UNIVERSITY   (Japan)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e PAN AMERICAN HEALTH ORGANIZATION   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Diarrhea; Rotavirus; Rotavirus vaccination; Vaccine effectiveness

Indexed keywords

BOVINE ROTAVIRUS VACCINE; CHOLERA VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE; RHESUS TETRAVALENT ROTAVIRUS VACCINE; RHEUS ROTAVIRUS VACCINE; ROTAVIRUS VACCINE; RV 1; RV 5; UNCLASSIFIED DRUG; VIRUS VACCINE; WC 3; WC 3 VACCINE;

AFRICA; ASIA; AUSTRALIA; AUSTRIA; BRAZIL; CHILDHOOD; CHILDHOOD DISEASE; CLINICAL TRIAL; DEVELOPING COUNTRY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EL SALVADOR; EPIDEMIOLOGICAL DATA; EUROPE; HERD IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INNATE IMMUNITY; MEXICO; MORTALITY; NICARAGUA; NONHUMAN; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ROTAVIRUS; SYMPTOM; VACCINATION; VIRAL GASTROENTERITIS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; WESTERN HEMISPHERE; WORLD HEALTH ORGANIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); HEALTH; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; ROTAVIRUS INFECTIONS; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; GLOBAL HEALTH; HUMANS; IMMUNIZATION PROGRAMS; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; WORLD HEALTH ORGANIZATION;

EID: 77950616537     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.17     Document Type: Review

References (130)

1. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis. 12(2), 304-306 (2006).
2. Parashar UD, Burton A, Lanata C et al. Global mortality associated with rotavirus disease among children in 2004. J. Infect. Dis. 200(Suppl. 1), S9-S15 (2009).
3. Glass RI, Bresee JS, Turcios R, Fischer TK, Parashar UD, Steele AD. Rotavirus vaccines: targeting the developing world. J. Infect. Dis. 192(Suppl. 1), S160-S166 (2005).
4. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N. Engl. J. Med. 354(1), 11-22 (2006).
5. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354(1), 23-33 (2006). (Pubitemid 43048948)
6. Conclusions and recommendations from the Immunization Strategic Advisory Group. Wkly Epidemiol. Rec. 81(1), 2-11 (2006).
7. Meeting of the immunization Strategic Advisory Group of Experts, April 2009-conclusions and recommendations. Wkly Epidemiol. Rec. 84(23), 220-236 (2009).
8. Rotavirus vaccines: an update. Wkly Epidemiol. Rec. 84(51-52), 533-540 (2009).
9. Meeting of the Strategic Advisory Group of Experts on immunization, October 2009-conclusions and recommendations. Wkly Epidemiol. Rec. 84(50), 517-532 (2009).
10. Estes MK, Cohen J. Rotavirus gene structure and function. Microbiol. Rev. 53(4), 410-449 (1989).
11. Estes MK, Kapikian AZ. Rotaviruses. In: Field's Virology (5th Edition). Knipe DM, Howley PM (Eds). Lippincott, Williams and Williams, PA, USA, 1917-1958 (2007).
12. Gentsch JR, Parashar UD, Glass RI. Impact of rotavirus vaccination: the importance of monitoring strains. Future Microbiol. 4, 1231-1234 (2009).
13. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 272(5258), 101-104 (1996).
14. Rodriguez WJ, Kim HW, Brandt CD et al. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr. Infect. Dis. J. 6(2), 170-176 (1987).
15. Glass RI, Kilgore PE, Holman RC et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J. Infect. Dis. 174(Suppl. 1), S5-S11 (1996).
16. Gurwith M, Wenman W, Hinde D, Feltham S, Greenberg H. A prospective study of rotavirus infection in infants and young children. J. Infect. Dis. 144(3), 218-224 (1981).
17. Carlson JA, Middleton PJ, Szymanski MT, Huber J, Petric M. Fatal rotavirus gastroenteritis: an analysis of 21 cases. Am. J. Dis. Child. 132(5), 477-479 (1978).
18. Blutt SE, Matson DO, Crawford SE et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med. 4(4), e121 (2007).
19. Blutt SE, Kirkwood CD, Parreno V et al. Rotavirus antigenaemia and viraemia: a common event? Lancet 362(9394), 1445-1449 (2003).
20. Chiappini E, Azzari C, Moriondo M, Galli L, de Martino M. Viraemia is a common finding in immunocompetent children with rotavirus infection. J. Med. Virol. 76(2), 265-267 (2005).
21. Chitambar SD, Tatte VS, Dhongde R, Kalrao V. High frequency of rotavirus viremia in children with acute gastroenteritis: discordance of strains detected in stool and sera. J. Med. Virol. 80(12), 2169-2176 (2008).
22. Ray P, Fenaux M, Sharma S et al. Quantitative evaluation of rotaviral antigenemia in children with acute rotaviral diarrhea. J. Infect. Dis. 194(5), 588-593 (2006).
23. Velazquez FR, Matson DO, Calva JJ et al. Rotavirus infections in infants as protection against subsequent infections. N. Engl. J. Med. 335(14), 1022-1028 (1996).
24. Black RE, Lopez de Romana G et al. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru. Am. J. Epidemiol. 129(4), 785-799 (1989).
25. Mrukowicz J, Szajewska H, Vesikari T. Options for the prevention of rotavirus disease other than vaccination. J. Pediatr. Gastroenterol. Nutr. 46(Suppl. 2), S32-S37 (2008).
26. Simhon A, Mata L, Vives M et al. Low endemicity and low pathogenicity of rotaviruses among rural children in Costa Rica. J. Infect. Dis. 152(6), 1134-1142 (1985).
27. Zaki AM, DuPont HL, el Alamy MA et al. The detection of enteropathogens in acute diarrhea in a family cohort population in rural Egypt. Am. J. Trop. Med. Hyg. 35(5), 1013-1022 (1986).
28. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N. Engl. J. Med. 309(2), 72-76 (1983).
29. Snodgrass DR, Wells PW. Rotavirus infection in lambs: studies on passive protection. Arch. Virol. 52(3), 201-205 (1976).
30. Midthun K, Kapikian AZ. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 9(3), 423-434 (1996). (Pubitemid 26245619)
31. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1(8384), 977-981 (1984). (Pubitemid 14148890)
32. Vesikari T, Isolauri E, Delem A et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J. Pediatr. 107(2), 189-194 (1985). (Pubitemid 15241906)
33. Ruuska T, Vesikari T, Delem A, Andre FE, Beards GM, Flewett TH. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period. Scand J. Infect. Dis. 22(3), 269-278 (1990).
34. Vesikari T. Clinical trials of live oral rotavirus vaccines: the Finnish experience. Vaccine 11(2), 255-261 (1993). (Pubitemid 23031516)
35. Vesikari T, Ruuska T, Delem A, Andre FE. Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatr. Infect. Dis. J. 6(2), 164-169 (1987). (Pubitemid 17116136)
36. Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr. Scand. 80(2), 173-180 (1991).
37. Hanlon P, Hanlon L, Marsh V et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1(8546), 1342-1345 (1987). (Pubitemid 17076248)
38. De Mol P, Zissis G, Butzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 2(8498), 108 (1986). (Pubitemid 16097112)
39. Lanata CF, Black RE, del Aguila R et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J. Infect. Dis. 159(3), 452-459 (1989). (Pubitemid 19065891)
40. Georges-Courbot MC, Monges J, Siopathis MR et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res. Virol. 142(5), 405-411 (1991).
41. Flores J, Perez-Schael I, Gonzalez M et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1(8538), 882-884 (1987). (Pubitemid 17050273)
42. Perez-Schael I, Garcia D, Gonzalez M et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J. Med. Virol. 30(3), 219-229 (1990). (Pubitemid 20146247)
43. Pérez-Schael I, Guntiñas MJ, Pérez M et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med. 337, 1181-1187 (1997). (Pubitemid 27454449)
44. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350(9086), 1205-1209 (1997). (Pubitemid 127445093)
45. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 273(15), 1191-1196 (1995).
46. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 48(RR-2), 1-20 (1999).
47. Withdrawal of rotavirus vaccine recommendation. MMWR Morb. Mortal. Wkly Rep. 48(43), 1007 (1999).
48. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb. Mortal. Wkly Rep. 48(27), 577-581 (1999).
49. Murphy TV, Gargiullo PM, Massoudi MS et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344(8), 564-572 (2001). (Pubitemid 32167870)
50. Peter G, Myers MG. Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 110(6), e67 (2002).
51. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time of vaccination. J. Infect. Dis. 192(Suppl. 1), S36-S43 (2005). (Pubitemid 41193100)
52. Rothman KJ, Young-Xu Y, Arellano F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J. Infect. Dis. 193(6), 898; author reply 898-899 (2006).
53. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Wkly Epidemiol. Rec. 81(2), 15-19 (2006).
54. International Medica Foundation. Milestone in Phase II Clinical Trial for Rotavirus Vaccine Reached. International Medica Foundation, MN, USA (2009).
55. Heaton PM, Goveia MG, Miller JM, Offit P, Clark HF. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J. Infect. Dis. 192(Suppl. 1), S17-S21 (2005). (Pubitemid 41193097)
56. Bernstein DI, Smith VE, Sherwood JR et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 16(4), 381-387 (1998).
57. De Vos B, Vesikari T, Linhares AC et al. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 23(10 Suppl.), S179-S182 (2004). (Pubitemid 44146429)
58. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370(9601), 1757-1763 (2007). (Pubitemid 350137490)
59. Linhares AC, Velazquez FR, Perez-Schael I et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled Phase III study. Lancet 371(9619), 1181-1189 (2008).
60. Keating GM. Rotavirus vaccine RIX4414 (Rotarix). Paediatr. Drugs 8(6), 389-395; discussion 396-1387 (2006).
61. De Vos B, Han HH, Bouckenooghe A et al. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr. Infect. Dis. J. 28(4), 261-266 (2009).
62. Madhi SA, Cunliffe NA, Steele AD et al. Impact of human rotavirus vaccine on severe gastroenteritis in African infants: a multicentre clinical trial. N. Engl. J. Med. 362(4), 289-298 (2010).
63. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 58(RR-2), 1-25 (2009).
64. Boom JA, Tate JE, Sahni LC et al. Effectiveness of Pentavalent rotavirus vaccine in a large, urban US population. Pediatrics 125(2), e199-e207 (2010).
65. Tate JE, Panozzo CA, Payne DC et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 124(2), 465-471 (2009).
66. Reduction in rotavirus after vaccine introduction-United States, 2000-2009. MMWR Morb. Mortal. Wkly Rep. 58(41), 1146-1149 (2009).
67. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in children and correlation with early rotavirus vaccine uptake from a national medical claims database. Pediatr. Infect. Dis. J. (2010) (In Press).
68. Lambert SB, Faux CE, Hall L et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med. J. Aust. 191(3), 157-160 (2009).
69. Snelling TL, Schultz R, Graham J et al. Rotavirus and the indigenous children of the Australian outback: monovalent vaccine effective in a high-burden setting. Clin. Infect. Dis. 49(3), 428-431 (2009).
70. Snelling TL, Andrews RM, Kirkwood CD, Carapetis JR. Evaluation of the monovalent human rotavirus vaccine RIX4414 following a G2P[4] outbreak. Presented at: 26th meeting of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12-15 September 2009.
71. Paulke-Korinek M, Rendi-Wagner P, Kundi M, Kronik R, Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in austrian children. Pediatr. Infect. Dis. J. DOI: 10.1097/ INF.0b013e3181c18434 (2009).
72. Gurgel RQ, Cuevas LE, Vieira SC et al. Predominance of rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis. 13(10), 1571-1573 (2007).
73. Gurgel RQ, Correia JB, Cuevas LE. Effect of rotavirus vaccination on circulating virus strains. Lancet 371(9609), 301-302 (2008). (Pubitemid 351754783)
74. Nakagomi T, Cuevas LE, Gurgel RG et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch. Virol. 153(3), 591-593 (2008).
75. Gurgel RQ, Bohland AN, Vieira SA et al. Incidence of rotavirus and all-cause diarrhea in northeast brazil following the introduction of a national vaccination program. Gastroenterology 137, 1970-1975 (2009).
76. Patel MM, de Oliveira LH, Bispo AM, Gentsch J, Parashar UD. Rotavirus P[4]G2 in a vaccinated population, Brazil. Emerg. Infect. Dis. 14(5), 863-865 (2008).
77. Correia JB, Patel MM, Nakagomi O et al. Effectiveness of monovalent rotavirus vaccine (rotarix) against severe diarrhoea caused by serotypically-unrelated G2P[4] strains in Brazil. J. Infect. Dis. 201(3), 363-369 (2010).
78. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M et al. Reduction in childhood diarrhea deaths after rotavirus vaccine introduction in Mexico. N. Engl. J. Med. 362(4), 299-305 (2010).
79. Patel M, Pedreira C, De Oliveira LH et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301(21), 2243-2251 (2009).
80. Orozco M, Vasquez J, Pedreira C et al. Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua. J. Infect. Dis. 200(Suppl. 1), S125-S130 (2009).
81. Belongia EA, Irving SA, Shui IM et al. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr. Infect. Dis. J. 29(1), 1-5 (2010).
82. Haber P, Patel M, Izurieta HS et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 121(6), 1206-1212 (2008).
83. Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD. Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev. Vaccines 8(11), 1555-1564 (2009).
84. Patel NC, Hertel PM, Estes MK et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N. Engl. J. Med. 362(4), 314-319 (2010).
85. RotaTeq® (Package Insert). Merck & Co., Inc., NJ, USA (2009)
86. Zaman K, Sack DA, Yunus M et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 27(9), 1333-1339 (2009).
87. Ciarlet M, Sani-Grosso R, Yuan G et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr. Infect. Dis. J. 27(10), 874-880 (2008).
88. Patel MM, Clark AD, Glass RI et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 27(22), 2916-2922 (2009).
89. Clark A, Sanderson C. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 373(9674), 1543-1549 (2009).
90. John TJ. Antibody response of infants in tropics to five doses of oral polio vaccine. Br. Med. J. 1(6013), 812 (1976).
91. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol. 96(4), 263-269 (1972).
92. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev. Infect. Dis. 13(5), 926-939 (1991).
93. Suharyono, Simanjuntak C, Witham N et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 340(8821), 689-694 (1992).
94. Gotuzzo E, Butron B, Seas C et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61(9), 3994-3997 (1993). (Pubitemid 23260079)
95. Linhares AC, Gabbay YB, Mascarenhas JD et al. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull. World Health Organ. 74(5), 491-500 (1996).
96. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J. Infect. Dis. 200(Suppl. 1), S39-S48 (2009).
97. Glass RI, Parashar UD, Bresee JS et al. Rotavirus vaccines: current prospects and future challenges. Lancet 368(9532), 323-332 (2006). (Pubitemid 44067224)
98. Rennels MB. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J. Infect. Dis. 174(Suppl. 1), S107-S111 (1996).
99. Moon KB. Differential rotavirus antibody profiles in breast milk specimens from mothers with infants in developed and developing countries. Presented at: American Society for Virology Conference. Vancouver, BC, Canada, 11-15 July 2009.
100. Steele AD, De Vos B, Tumbo J et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine DOI:10.1016/j. vaccine.2008.08.034 (2008) (Epub ahead of print).
101. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev. Med. Virol. 15(1), 29-56 (2005). (Pubitemid 40070041)
102. Sanchez-Padilla E, Grais RF, Guerin PJ, Steele AD, Burny ME, Luquero FJ. Burden of disease and circulating serotypes of rotavirus infection in sub-Saharan Africa: systematic review and meta-analysis. Lancet Infect. Dis. 9(9), 567-576 (2009).
103. Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 21(5-6), 361-367 (2003). (Pubitemid 36091925)
104. Vesikari T, Karvonen A, Puustinen L et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr. Infect. Dis. J. 23(10), 937-943 (2004). (Pubitemid 40812781)
105. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J. Infect. Dis. 200(Suppl. 1), S291-S299 (2009).
106. Matthijnssens J, Bilcke J, Ciarlet M et al. Rotavirus disease and vaccination: impact of genotype diversity. Future Microbiol. 4(10), 1303-1316 (2009).
107. Kirkwood C, Boniface C, Barnes G, Bishop R. Rotavirus genotype distribution in Australian children-what has happened during the first 18 months after introduction of RotaTeq™ and Rotarix™. Presented at: Vaccines for Enteric Diseases Meeting. Malaga, Spain, 9-11 September 2009.
108. Gurgel RQ, Correia JB, Cuevas LE. Effect of rotavirus vaccination on circulating virus strains [comment]. Lancet 371(9609), 301-302 (2008).
109. Leite JP, Carvalho-Costa FA, Linhares AC. Group A rotavirus genotypes and the ongoing Brazilian experience: a review. Mem. Inst. Oswaldo Cruz. 103(8), 745-753 (2008).
110. Nakagomi T, Cuevas LE, Gurgel RG et al. Apparent extinction of non-G2 rotavirus strains from circulation in Recife, Brazil, after the introduction of rotavirus vaccine. Arch. Virol. 153(3), 591-593 (2008).
111. Patel MM, de Oliveira LH, Bispo AM et al. Rotavirus P[4]G2 in a vaccinated population, Brazil [comment]. Emerg. Infect. Dis. 14(5), 863-865 (2008).
112. Hull J, Teel E, Kerin T et al. Report of the U.S. rotavirus strain surveillance (1996-2008). Presented at: American Society for Microbiology Meeting. BC, Canada, 17-21 July 2009.
113. Payne DC, Szilagyi PG, Staat MA et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr. Infect. Dis. J. 28(11), 948-953 (2009).
114. Bhandari N, Sharma P, Taneja S et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 200(3), 421-429 (2009).
115. Bhandari N, Sharma P, Glass RI et al. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 24(31-32), 5817-5823 (2006). (Pubitemid 43947390)
116. Barnes GL, Lund JS, Adams L et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J. Paediatr. Child Health 33(4), 300-304 (1997). (Pubitemid 27396182)
117. Barnes GL, Lund JS, Mitchell SV et al. Early Phase II trial of human rotavirus vaccine candidate RV3. Vaccine 20(23-24), 2950-2956 (2002).
118. Ruiz LP Jr. Rotavirus vaccines. N. Engl. J. Med. 354(16), 1747-1751; author reply 1747-1751 (2006).
119. Kapikian AZ, Simonsen L, Vesikari T et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J. Infect. Dis. 192(Suppl. 1), S22-S29 (2005). (Pubitemid 41193098)
120. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea. J. Infect. Dis. 168(2), 282-287 (1993). (Pubitemid 23210600)
121. Vethanayagam RR, Ananda Babu M, Nagalaxmi KS et al. Possible role of neonatal infection with the asymptomatic reassortant rotavirus (RV) strain I321 in the decrease in hospital admissions for RV diarrhea, Bangalore, India, 1988-1999. J. Infect. Dis. 189(12), 2282-2289 (2004). (Pubitemid 38757201)
122. Mohan KV, Kulkarni S, Glass RI, Zhisheng B, Atreya CD. A human vaccine strain of lamb rotavirus (Chinese) NSP4 gene: complete nucleotide sequence and phylogenetic analyses. Virus Genes 26(2), 185-192 (2003). (Pubitemid 36649161)
123. Fu C, Wang M, Liang J, He T, Wang D, Xu J. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine 25(52), 8756-8761 (2007). (Pubitemid 350192064)
124. Ciarlet M, Crawford SE, Barone C et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J. Virol. 72(11), 9233-9246 (1998). (Pubitemid 28471870)
125. Jiang B, Estes MK, Barone C et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17(7-8), 1005-1013 (1999). (Pubitemid 29074757)
126. Herrmann JE, Chen SC, Fynan EF et al. Protection against rotavirus infections by DNA vaccination. J. Infect. Dis. 174(Suppl. 1), S93-S97 (1996). (Pubitemid 26293128)
127. Coffin SE, Klinek M, Offit PA. Induction of virus-specific antibody production by lamina propria lymphocytes following intramuscular inoculation with rotavirus. J. Infect. Dis. 172(3), 874-878 (1995).
128. Conner ME, Crawford SE, Barone C, Estes MK. Rotavirus vaccine administered parenterally induces protective immunity. J. Virol. 67(11), 6633-6641 (1993). (Pubitemid 23309130)
129. Jiang B, Gentsch JR, Glass RI. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 26(52), 6754-6758 (2008).
130. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9(5), 565-572 (2003).